A new report contributes to the promising Bumetanide treatment for autism. Further studies should confirm this approach
The new publication by the team of Christopher Gillberg in Sweden extends previous positive observations and adds important information to the numerous previous trials on using Bumetanide to treat autistic children. Even though they performed an open-label trial of just six children (3-14 years old), it is important to note that all the participants had severe ASD (CARS score above 39) without comorbidities … Read more
